Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Sponsor: National Cancer Institute (NCI)
This PHASE2 trial investigates Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation and Castration-Resistant Prostate Carcinoma and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 53 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
53 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 48 earlier versions
-
Oct 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE2
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Aug 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Feb 2017 — May 2017 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .